双胎且有单胎自发性早产史者肌注孕酮的效果
本研究为回顾性队列研究,纳入79例双胎妊娠且有单胎自发性早产史孕妇,比较每周肌注17α-羟孕酮己酸酯(17-OHPC)与未用药者的结局。结果显示,干预组与对照组在<34周双胎自发性早产(59% vs 46%,OR 1.69,95%CI 0.68-4.54)及复合新生儿发病率(74% vs 79%,OR 0.76,95%CI 0.27-2.12)上均无统计学差异。结论认为每周肌注17-OHPC未能预防早产或新生儿疾病,需更大样本前瞻性研究验证。
要点
- 双胎且有单胎自发性早产史者,每周肌注17-OHPC未降低<34周自发性早产风险。
- 干预组与对照组复合新生儿发病率无显著差异(OR 0.76,95%CI 0.27-2.12)。
- 现有证据不支持该人群常规使用肌注孕酮预防早产,需个体化决策。
核心结论
- 在双胎妊娠且有单胎自发性早产史的妇女中,每周肌注17-OHPC未能预防自发性早产或降低新生儿发病率。
研究设计与样本
- 回顾性队列研究,纳入2005年1月至2016年12月两家机构的79例双胎妊娠且有单胎自发性早产史孕妇,27例接受每周肌注17-OHPC,52例未接受。
主要发现
- <34周双胎自发性早产发生率干预组59%(16例) vs 对照组46%(24例),OR 1.69(95%CI 0.68-4.54)。
- 复合新生儿发病率干预组74%(20例) vs 对照组79%(41例),OR 0.76(95%CI 0.27-2.12)。
- 调整潜在混杂因素后,结局差异仍无统计学意义。
关键数值与推荐
- 主要结局为<34周双胎自发性早产,采用OR及调整OR比较。
- 次要结局为复合新生儿发病率,包括呼吸窘迫综合征、脑室内出血、坏死性小肠结肠炎、新生儿重症监护入院及出院前胎儿或新生儿死亡。
临床怎么用
- 对于双胎妊娠且有单胎自发性早产史者,不应仅基于早产史常规推荐每周肌注17-OHPC预防早产。
- 临床决策需结合个体情况,并与患者充分沟通现有证据的局限性。
局限性
- 回顾性队列设计,样本量小(共79例),可能存在选择偏倚和混杂。
- 作者指出需要更大样本的前瞻性研究进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although the use of 17-alpha-hydroxyprogesterone caproate is one of the most commonly used strategies to reduce the risk of preterm birth since its approval by the Food and Drug Administration in 2011, there has been controversy recently that there may be no benefit associated with its use in singleton pregnancies in women with a prior history of spontaneous preterm birth. However, very few of these investigations evaluated the use of intramuscular progesterone in twin pregnancies. A few studies that used 17-alpha-hydroxyprogesterone caproate in twin pregnancies had mainly included unselected twin pregnancies. Although a twin pregnancy is independently associated with an increased likelihood of preterm birth, the primary indication for the use of supplemental progesterone in pregnancy is prior history of spontaneous preterm birth. Therefore, our investigation of weekly intramuscular progesterone in twin pregnancies with this birth history best addresses this question using a selected cohort. OBJECTIVE: To assess whether weekly 17-alpha-hydroxyprogesterone caproate prevents recurrent preterm birth in women with a current twin pregnancy and a prior singleton spontaneous preterm birth. STUDY DESIGN: This was a retrospective cohort study of women with twin pregnancy and a prior singleton spontaneous preterm birth in 2 institutions between January 2005 and December 2016. One group (intervention group) consisted of women who received weekly 17-alpha-hydroxyprogesterone caproate, whereas the other (control group) did not. The primary outcome was twin spontaneous preterm birth <34 weeks compared with odds ratio and adjusted odds ratio, adjusting for potential confounders. Secondary outcomes included composite neonatal morbidity such as respiratory distress syndrome, intraventricular hemorrhage, necrotizing enterocolitis, admission to the neonatal intensive care nursery, and fetal or neonatal death before hospital discharge. RESULTS: A total of 79 patients were included; 27 women received weekly 17-alpha-hydroxyprogesterone caproate and 52 did not. There were no statistically significant differences in maternal demographics except for age. Spontaneous preterm birth <34 weeks occurred in 16 patients (59%) in the intervention group vs 24 (46%) in the control group (odds ratio, 1.69; 95% confidence interval, 0.68-4.54). Composite neonatal morbidity occurred in 20 pregnancies (74%) in the intervention group and 41 pregnancies (79%) in the control group (odds ratio, 0.76; 95% confidence interval, 0.27-2.12). There remained no differences in outcomes after adjusting for potential confounders. CONCLUSION: In our study, weekly 17-alpha-hydroxyprogesterone caproate did not prevent spontaneous preterm birth or neonatal morbidity in women with twins and a prior singleton spontaneous preterm birth; however, further research with larger numbers and prospective design is needed.
引用
- Ward A, Greenberg V, Valcarcel B, et al. Intramuscular progesterone in women with twins and a prior singleton spontaneous preterm birth. Am J Obstet Gynecol MFM. 2020. PMID: 33345870. doi:10.1016/j.ajogmf.2020.100124
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。